Our therapeutic solutions

Making the fight against cancer our priority

Image
gélules jaune et orange

Recognized expertise

The objective of our cancer research is to improve the treatment of patients suffering from pathologies for which there are significant unmet therapeutic needs, always staying true to the group's values, and with the objective of contributing to the better-being of individuals.

Pierre Fabre provides therapeutic solutions to treat different types of cancer:

  • melanomas by oral targeted therapy
  • lung cancers by intravenous or oral chemotherapy
  • breast cancers by intravenous, oral chemotherapy, or oral targeted therapy
  • bladder cancers by intravenous chemotherapy

To go ever further in cancer research, we target fields where there are major medical needs: solid tumors and liquid tumors (leukemias). In 2015 we initiated a process of transforming our activities to establish a pipeline of future treatments, both via partnership agreements with

biotechs and research laboratories, and by accelerating our internal research.
Major partnerships have been formed, notably that with Array BioPharma in connection with the development of two molecules which specifically inhibit two mechanisms involved in some cancers.

 

 


 

 

Image
video Pierre Fabre Oncologie

Oncology: a priority for the Pierre Fabre Group

Pioneers in the field of oncology, today Pierre Fabre makes this a priority research area and is involved in the fight against cancer throughout the world.

0

Vinorelbine is synthesized and patented by the CNRS (French National Center for Scientific Research)

Image
oncopole recherche
0

Navelbine is registered in France

Image
oncopole site
0

Registration in France of Navelbine for a 2nd indication

Image
patient aide reponses therapeutiques
0

Launch of Navelbine oral

Image